HealthAccess expands for experimental weight-loss drug

Eli Lilly says it is widening access to retatrutide, an experimental drug for weight loss that has not yet received FDA approval. The company reports that obese patients in clinical trials lost between 73 and 85 pounds over two years while taking it. Dr. Rachel Pessah Pollack discusses what is known about the drug’s safety and who may qualify to receive it. The report focuses on the medication’s early clinical-trial results and access.